Sinopharm WIBP COVID-19 vaccine
GPTKB entity
Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:adjuvant |
aluminum hydroxide
|
| gptkbp:antigen |
inactivated SARS-CoV-2 virus
|
| gptkbp:approvedBy |
2020
|
| gptkbp:associatedWith |
gptkb:Sinopharm_BIBP_COVID-19_vaccine
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:countryOfOrigin |
gptkb:China
|
| gptkbp:developedBy |
gptkb:Wuhan_Institute_of_Biological_Products
gptkb:Sinopharm |
| gptkbp:dosingSchedule |
two doses
|
| gptkbp:effect |
72.5% (reported in clinical trials)
|
| gptkbp:emergencyServices |
gptkb:China
|
| gptkbp:foundIn |
gptkb:China
gptkb:Morocco gptkb:Pakistan gptkb:Serbia gptkb:United_Arab_Emirates |
| https://www.w3.org/2000/01/rdf-schema#label |
Sinopharm WIBP COVID-19 vaccine
|
| gptkbp:otherName |
gptkb:WIBP-CorV
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:storage |
2–8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
inactivated virus vaccine
|
| gptkbp:WHOStatus |
emergency use listing (EUL) not granted
|
| gptkbp:bfsParent |
gptkb:Sinopharm
|
| gptkbp:bfsLayer |
5
|